Vanguard Group Inc. Decreases Stock Position in AngioDynamics, Inc. (NASDAQ:ANGO)

Vanguard Group Inc. lessened its stake in AngioDynamics, Inc. (NASDAQ:ANGO) by 1.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,232,855 shares of the medical instruments supplier’s stock after selling 35,606 shares during the period. Vanguard Group Inc. owned approximately 0.06% of AngioDynamics worth $13,107,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Armistice Capital LLC purchased a new position in shares of AngioDynamics during the 4th quarter valued at $6,272,000. Fund 1 Investments LLC bought a new stake in AngioDynamics in the fourth quarter worth about $3,896,000. ADAR1 Capital Management LLC bought a new stake in AngioDynamics in the fourth quarter worth about $1,042,000. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of AngioDynamics by 48.7% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 201,854 shares of the medical instruments supplier’s stock worth $1,560,000 after acquiring an additional 66,117 shares during the period. Finally, Panagora Asset Management Inc. increased its position in shares of AngioDynamics by 19.8% during the fourth quarter. Panagora Asset Management Inc. now owns 218,803 shares of the medical instruments supplier’s stock worth $1,715,000 after acquiring an additional 36,150 shares during the period. Institutional investors own 89.43% of the company’s stock.

AngioDynamics Trading Up 1.2 %

Shares of NASDAQ ANGO opened at $7.53 on Wednesday. AngioDynamics, Inc. has a 12-month low of $5.26 and a 12-month high of $9.43. The stock has a market cap of $301.61 million, a PE ratio of -1.56 and a beta of 0.66. The company has a 50-day moving average of $6.56 and a 200 day moving average of $6.20.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Tuesday, July 16th. The medical instruments supplier reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.11. AngioDynamics had a negative net margin of 61.55% and a negative return on equity of 4.91%. The firm had revenue of $71.00 million for the quarter, compared to analyst estimates of $70.86 million. During the same period in the prior year, the business posted $0.02 EPS. The business’s revenue for the quarter was down 22.1% compared to the same quarter last year. On average, sell-side analysts forecast that AngioDynamics, Inc. will post -0.41 EPS for the current fiscal year.

Analyst Ratings Changes

ANGO has been the subject of several recent analyst reports. Canaccord Genuity Group lowered their target price on shares of AngioDynamics from $18.00 to $13.00 and set a “buy” rating for the company in a research note on Wednesday, July 17th. HC Wainwright restated a “buy” rating and set a $14.00 target price on shares of AngioDynamics in a research report on Wednesday, July 17th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $12.25.

About AngioDynamics

AngioDynamics, Inc provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease.